Pathology imaging systems market seen reaching $2.29B by 2030

The pathology imaging systems market is projected to grow from $1.37 billion in 2025 to $2.29 billion by 2030, driven by AI-assisted diagnostics, cloud platforms and more clinical trials. North America leads today, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Pathology imaging systems are becoming more important to faster, more precise diagnosis, especially in cancer and chronic disease. - The market expansion signals more spending on digital pathology tools that can support AI analysis, remote review and lab workflow integration. - Clinical research demand is also rising, which increases the need for high-resolution tissue imaging and biomarker detection.

What happened: - The pathology imaging systems market is projected to rise from $1.37 billion in 2025 to $1.52 billion in 2026. - The market is expected to reach $2.29 billion by 2030. - The forecast implies a 10.7% CAGR from 2025 to 2026 and a 10.9% CAGR from 2025 to 2030. - The Business Research Company published the outlook on July 21, 2026. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables.

The details: - Pathology imaging systems are digital platforms and devices that capture, store, analyze and share high-resolution images of tissue samples and laboratory specimens. - Manual microscopy, slow adoption of digital pathology, costly scanners, a shortage of skilled pathologists and limited data storage capacity have held back growth in recent years. - Growth through 2030 is expected to come from AI-assisted diagnostic tools, cloud-based pathology platforms, precision medicine demand, remote diagnostic services and tighter integration of hospital IT and imaging systems. - The report also points to telepathology, outsourced remote diagnostics, standardized whole slide imaging, stronger interoperability, centralized pathology labs serving multiple hospitals, regulatory validation of digital pathology and links between laboratory information systems and imaging workflows as key trends. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - Clinical trial activity is a major growth driver because pathology imaging supports tissue examination, biomarker detection and ongoing patient monitoring during research. - The Association of the British Pharmaceutical Industry reported that UK pharmaceutical-company clinical trials initiated rose from 411 in 2022 to 426 in 2023.

Between the lines: - The forecast reflects a broader shift from manual pathology toward software-enabled diagnostics and distributed review models. - The emphasis on interoperability and validation suggests the market is moving from early adoption toward more regulated, hospital-scale deployment. - The regional outlook suggests mature demand in North America and faster infrastructure buildout across Asia-Pacific.

What's next: - More pathology labs are likely to adopt AI-supported imaging and cloud workflows as digital infrastructure matures. - Companies in the sector may continue to focus on telepathology, centralized lab models and systems that connect laboratory and hospital software. - Regulatory and interoperability standards will remain important as digital pathology moves into wider clinical use.

The bottom line: - Pathology imaging systems are moving from a niche digital toolset to a core part of modern diagnostics, with growth anchored by AI, clinical research and connected lab workflows.